Philippe Aftimos, MD · @aftimosp · X·· 1 day agoScore70
Body
🔹CDK4 selective inh Atirmociclib + fulvestrant improved mPFS vs investigator’s choice post-CDK4/6i in the FourLight-1 ph2 trial
🔹Neutropenia the most frequent AE & 1 related pneumontis death
🔹Next step: the FourLight-3 ph3 study in the 1L vs CDK4/6i
#ESMO26 #ESMOAmbassadors
166 views · 1 like · 1 repost · 1 reply
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgReplies in this thread
- Philippe Aftimos, MD @aftimosp
Next steps: ❓Atirmociclib replacing CDK4/6i in triplets with ET and PIK3CAi? ❓Atirmociclib in the adjuvant setting? #ESMO26 #ESMOAmbassadors @myESMO
Source: Philippe Aftimos, MD · x.com